DRR168546
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.580
- INTERFERON_ALPHA_RESPONSE+0.360
- HEDGEHOG_SIGNALING+0.320
- KRAS_SIGNALING_DN+0.280
- INTERFERON_GAMMA_RESPONSE+0.260
- SPERMATOGENESIS+0.180
- TNFA_SIGNALING_VIA_NFKB+0.170
- HYPOXIA+0.160
- IL6_JAK_STAT3_SIGNALING+0.150
- ALLOGRAFT_REJECTION+0.130
Top 10 suppressed
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.330
- PROTEIN_SECRETION-0.310
- DNA_REPAIR-0.250
- MITOTIC_SPINDLE-0.210
- MYC_TARGETS_V1-0.200
- APOPTOSIS-0.180
- UV_RESPONSE_DN-0.170
- ANGIOGENESIS-0.160
- PI3K_AKT_MTOR_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD040_D.RNA-Seq | EPN | Supratentorial EPN | 0.734 |
| 2 | TCGA-BH-A2L8-01A-11R-A18M-07 | — | A | 0.709 |
| 3 | MNG1161 | — | — | 0.707 |
| 4 | BS_B1HVNV0T | ATRT | — | 0.705 |
| 5 | SRR12202413 | — | — | 0.702 |
| 6 | SJEPD001542_D1.RNA-Seq | EPN | Supratentorial EPN | 0.698 |
| 7 | TCGA-GD-A76B-01A-11R-A32O-07 | — | — | 0.698 |
| 8 | MNG428 | — | — | 0.696 |
| 9 | MNG279 | — | — | 0.694 |
| 10 | SRR13780258 | — | cohortMD2 | 0.693 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.580 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.090 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |